# Contributing to Cancer Alpha

Thank you for your interest in contributing to Cancer Alpha! This project is patent-protected technology with specific licensing requirements.

## 🔒 **Legal Requirements**

**IMPORTANT**: This project contains patent-protected technology (Provisional Patent No. 63/847,316). All contributions are subject to these legal requirements.

### For Contributors
- All contributions must be original work
- Contributors grant rights to incorporate their work into the patent-protected system
- Commercial use requires separate patent licensing

## 📋 **How to Contribute**

### Academic Contributions
- **Research collaborations**: Contact craig.stillwell@gmail.com
- **Bug reports**: Create issues with detailed descriptions
- **Documentation improvements**: Submit pull requests
- **Educational use cases**: Share your experiences

### What We Welcome
- 🐛 Bug reports and fixes
- 📚 Documentation improvements
- 🧪 Test cases and validation
- 💡 Research insights and feedback
- 🏥 Clinical use case studies

### What Requires Special Permission
- 🔬 Core algorithm modifications
- 🤖 New model implementations
- 🏭 Production deployment guidance
- 💼 Commercial applications

## 📝 **Contribution Process**

1. **Contact First**: For significant contributions, email craig.stillwell@gmail.com
2. **Fork & Branch**: Create a feature branch from main
3. **Test**: Ensure your changes don't break existing functionality
4. **Document**: Update relevant documentation
5. **Submit**: Create a pull request with clear description

## ⚖️ **Legal Disclaimer**

By contributing to this project, you acknowledge:
- The patent-protected nature of this technology
- Your contributions may be incorporated into commercial licenses
- Academic use only unless otherwise licensed

## 📧 **Contact**

- **General Questions**: Create a GitHub issue
- **Research Collaboration**: craig.stillwell@gmail.com
- **Commercial Licensing**: craig.stillwell@gmail.com

---

**© 2025 Dr. R. Craig Stillwell. Patent Pending - Provisional Application No. 63/847,316**
